The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Johnson & Johnson JNJ has announced the submission of a supplemental biologics license application (sBLA) seeking approval of its immunology medicine, Tremfya, for a new indication — moderately to ...
By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 19, 2020 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.
What Is Tremfya, and Why Does It Matter? Tremfya is a prescription biologic medicine used as an intravenous injection or under-the-skin shot for treating certain immune-related inflammatory diseases.
Eli Lilly knows it has a tough fight ahead for IL-17A med Taltz with challengers from Novartis and Johnson & Johnson on the march. But in a head-to-head battle with one—J&J’s Tremfya—Taltz has taken ...
Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for use in children from six years of age, following positive data from multiple phase ...
On July 13, 2017, the U.S. Food and Drug Administration approved Tremfya (guselkumab), a biologic manufactured by Janssen Biotech, for the treatment of moderate-to-severe plaque psoriasis patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results